By analyzing the infiltration of stromal cells in different GBM patients, we found that compared with those in newly diagnosed GBM patients or neoadjuvant non-responders, the cells that decreased the most were COL6A3+ TAFs in neoadjuvant responders. The gene discussed is COL6A3; the disease is glioblastoma.